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Abstract
Purpose: Compared with the rest of the United States, the population of Appalachia has lower
education levels, higher rates of poverty, and limited access to health care. The presence of dis-
parities in radiation therapy (RT) access for Appalachian patients with cancer has rarely been
examined.
Methods and materials: The National Cancer Institute initiatives toward addressing disparities in
treatment access for rural populations were examined. An extensive literature search was under-
taken for studies investigating RT access disparities in Appalachian patients, beginning with the
most common cancers in these patients (lung, colorectal, and cervical).
Results: Although the literature investigating RT access disparities in Appalachia is relatively
sparse, studies examining lung, colorectal, cervical, prostate, head and neck, breast, and esophageal
cancer, as well as lymphoma, indicate an unfortunate commonality in barriers to optimal RT access
for Appalachian patients with cancer. These barriers are predominantly socioeconomic in nature
(low income and lack of private insurance) but are exacerbated by paucities in both the number and
quality of radiation centers that are accessible to this patient population.
Conclusions: Regardless of organ system, there are significant barriers for Appalachian patients
with cancer to receive RT. Such diminished access is alarming and warrants resources devoted to
addressing these disparities, which often go overlooked because of the assumption that the overall
wealth of the United States is tangibly applicable to all of its citizens. Without intelligently targeted
investments of time and finances in this arena, there is great risk of exacerbating rather than
alleviating the already heavy burden facing Appalachian patients with cancer.
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Introduction
Optimal treatment of cancer requires access to the most
advanced tools of care, among which radiation therapy
(RT) is a prominent component.1 Given the advances in
radiation oncology technology and efficacy over the past
3 decades, disparities in RT access arguably result in
larger discrepancies in patient care than ever before.2 The
current Advances in Radiation Oncology disparities series
has focused on the vulnerable populations within the
United States that most likely to suffer disparities in RT
access and previously examined African American,
Native American, and Hispanic American patients.3e6
This manuscript concludes the series by investigating
the barriers Appalachian patients with cancer face in
receiving RT care, a population from which prior research
has produced important information for intervention,
research, and control of cancer.7
According to the Appalachian Regional Commission
(federally mandated in 1965 to support social and eco-
nomic development in the Appalachian region), Appa-
lachia comprises 406 counties that span 13 states
(Alabama, Georgia, Kentucky, Maryland, Mississippi,
New York, North Carolina, Ohio, Pennsylvania, South
Carolina, Tennessee, Virginia, and West Virginia) along
the Appalachian mountain chain, containing >8% of the
U.S. population.8 The Appalachian Regional Commission
is composed of the governors of these 13 states as well as
a presidential appointee who represents the federal gov-
ernment (most recently Earl Gohl in 2010).
However, a March 2017 federal budget proposal for
the 2018 fiscal year proposed the complete elimination of
Appalachian Regional Commission federal funding.8e10
Compared with the rest of the United States, Appala-
chians have lower education levels, higher rates of
poverty, and limited access to health care.11 Conse-
quently, the National Cancer Institute has designated any
rural population as a special population due to high death
risk from cancer and other diseases.12
An analysis of mortality by the Centers for Disease
Control National Center for Health Statistics using Sur-
veillance, Epidemiology, and End Results (SEER) data
from 1994 to 1998 found the cancer death rate for rural
Appalachia to be 176.3 per 100,000 people and 173.1 per
100,000 for all Appalachia, compared with the general
United States at 166.7 per 100,000 population.8 Death
rates for lung (57.2 vs 48.9 per 100,000) and cervical (3.1
vs 2.7 per 100,000) cancer were each significantly higher
in rural Appalachia than in the United States overall, with
the Appalachian region of Kentucky having the highest
death rate for lung cancer (73.7 per 100,000), cervical
cancer (3.8 per 100,000), and all cancers (196.6 per
100,000). The colorectal cancer death rate of 6 of 13
Appalachian states was significantly higher than that of
the overall U.S. rate of 16.9 per 100,000.8
The Centers for Disease Control attempted to address
these findings by promoting screening services through
the National Breast and Cervical Cancer Early Detection
Program and the National Colorectal Cancer Action
Campaign.13 The cancer with the largest impact on the
all-cancer death rate for Appalachian patients is lung
cancer, which has been attributed to a high prevalence of
smoking in this population.8
Most common cancer-related death sites in
Appalachian patients (lung, colorectal, cervical)
Lung cancer
Overall, lung cancer has a higher incidence in Appa-
lachia than non-Appalachia areas of the United States. In
a recent review by Wilson et al., the male rate of lung and
bronchus cancer incidence is 100.4 cases per 100,000
persons, and the female rate is 61.0 per 100,000. This is
relatively higher than the rates in the U.S. non-Appalachia
areas, with 79.5 cases per 100,000 for men and 54.7 cases
per 100,000 for women.14 Moreover, for both female and
male Appalachian residents, there has been a steady
increase of 1.4% for men and 0.6% for women.14 A
higher incidence has been attributed to lifestyle, occupa-
tion, low income, and lack of education.15,16
Rural areas tend to have variations in quality, avail-
ability, and access to medical services compared with
metro areas.17 In North Carolina, surveys showed that
among respondent rural facilities, only 52% followed
lung cancer screening guidelines. Moreover, in the active
facilities, overall patient volumes were low.18 However,
when a free lung screening program was implemented in
the southeastern United States, a 2-fold increase in
prevalence was found compared with the National Lung
Screening Trial.19 This indicates that more patients can be
diagnosed if guidelines are followed.
Along with higher incidence and poor access to facil-
ities for preventative services in Appalachia, several de-
mographic factors serve as a barrier to obtaining
treatment, specifically RT. Whether radiation is received
by patients with non-small cell lung cancer in rural areas
based on demographic factors have been reviewed by
several studies. In a study performed in Georgia, higher
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disease stage and number of comorbidities were associ-
ated with less radiation receipt, but race was not.
Interestingly, nonmetropolitan area residents had a
higher probability of receiving radiation compared with
patients residing in metropolitan areas.20 In this particular
study, this counterintuitive finding was explained by the
fact that even though travel distances were greater for
patients in rural areas, many radiation facilities provided
transportation to help minimize the gap in care. In gen-
eral, 26.3% of patients did not receive any therapy within
a year of diagnosis. These patients were more likely to be
older and without insurance coverage.20 In rural areas of
Alabama, race was not a significant factor for RT receipt,
which was the case in urban areas.21 This may highlight
that racial disparities tend to become minimal in the
context of Appalachian locations.
Factors leading to disparities in rural areas (eg, age)
have been found to translate to worse outcomes. In rural
West Virginia, elderly patients had significantly better
survival outcomes with lung cancer if they received the
appropriate therapy, which may be surgery plus RT and
chemotherapy. Appropriate care was only received by
46% of patients in the cohort and was not affected by
timeliness of care. The disparity was attributed to the
disproportionate lung cancer burden, facilities in the area
that did not completely follow guideline concordant care,
and underuse of diagnostic and management services of
Medicare.22 Another study evaluating disparities in cancer
care in West Virginia noted that the supply and proximity
of radiation oncologist and facilities may contribute to the
significant disparity. Of note, the author urges large uni-
versity centers in the area to develop radiation oncology
residency programs to ensure a better cancer care
workforce.23
Lung cancer is a prominent burden in the Appalachian
population compared with the U.S. non-Appalachian
population because of many demographic and lifestyle
factors. However, the difficulty of access to radiation fa-
cilities with adequate resources to guideline-driven prac-
tices provides a significant barrier to obtaining radiation if
necessary and can subsequently translate to worse
outcomes.
Colorectal cancer
The incidence of colon cancer in Appalachia is 56.6
per 100,000 persons for men and 41.8 per 100,000 for
women. These statistics are higher than those of non-
Appalachian men and women in the United States.14
When comparing rural and non-rural Appalachia using
SEER data, Appalachia incidence was found to be
greater than what was shown in the SEER data.24
Moreover, the incidence of unstaged colon and rectal
cancer in rural Appalachia was substantially elevated,
which translated to access to and use of diagnostic and
treatment services.24
In Kentucky, patients from Appalachian counties were
half as likely to have a colonoscopy or sigmoidoscopy
performed within the past 10 years compared with non-
Appalachian patients.25 Recent data also suggest
decreased odds of receiving RT for rural Georgia resi-
dents.26 Treatment access and use has great implication in
terms of outcomes. The presence of a radiation facility in
a county in Appalachia results in a 12% to 47% decline in
mortality.27
Beyond a higher incidence and barriers to access of
care, up-to-date medical facilities are scarce as well.
Hatzell et al performed a study evaluating the impact of
educational activities updating on newer methodologies in
colon and rectal treatments. Pre-and-post surveys showed
that 70% of participants failed to acknowledge chemo-
therapy as experimental for patients with Dukes’ B colon
cancer, and 25% failed to recognize a combination of
surgery, chemotherapy, and RT as a standard treatment
for rectal cancer. The authors concluded that a stronger
consensus for appropriate cancer treatment is necessary.28
The disparity in colon and rectal cancer in Appalachia
is a domino effect that starts with inadequate screening
and leads to the scarcity of radiation facilities in the vi-
cinity. Additionally, rural facilities may not be up to date
on recent guidelines, and patients may not be receiving
standard of care in terms of RT. However, other factors
such as race and socioeconomic factors have not been
completely elucidated. Further research on the specific
barriers to receipt of adequate radiation in colorectal
cancer should be further explored and described.
Cervical cancer
The epidemiology, risk factors, and clinical outcome
of patients with cervical cancer are closely related to race,
smoking, and poor socioeconomic status. In a study of
153 women by the University of Maryland,29 African-
American women were more likely to have stages III
and IV cervical cancer and had poorer survival across all
stages of disease compared with white women. Another
study30 by the same institution noted that being African
American and/or having Medicaid or uninsured status
were associated with more emergency visits and admis-
sions for cervical cancer and treatment-related complica-
tions in the Appalachian regions. In a large study of
>2000 patients, alarmingly increased rates of African-
American women were found to have locally advanced
or stage IV cervical cancer at diagnosis, even after
adjusting for insurance status, compared with their white
counterparts.31 However, there is certainly good news as
well: At a large and experienced tertiary hospital in
Kentucky with patients with cervical cancer, no differ-
ences were observed by race, insurance coverage, or so-
cioeconomic status in patient outcomes including survival
over a 10-year period.32 Furthermore, the increased case
volumes of the medical facility were proportionally
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related to improved cervical cancer outcomes in a study
using the Virginia state cancer registry.33
Additional cancer sites in Appalachian patients
Prostate cancer
Data on the use of RT for the Appalachian region is
limited; however, current studies suggest that RT dis-
parities may indeed exist. The Virginia Prostate Cancer
registry was published, analyzing 28,244 men with stage
0 to IV prostate cancer between 1970 and 1997.34 Only
3.3% had stage 0 disease and 13.2% had stage IV at
diagnosis. The registry showed that the first course of
treatment for the entire cohort consisted of surgery alone
for 9632 patients (34.1%) and radiation alone for 5556
patients (19.7%). Combined surgery and radiation were
given to 898 patients (3.2%), surgery and hormone ther-
apy to 1398 patients (4.9%), and RT and hormone therapy
to 1246 patients (4.4%). The article compared the results
to those of a prior National Cancer Database on prostate
cancer statistics, which showed a similar national trend
with surgery alone in 41.0% and radiation only in 22.0%
of patients for first-line treatment.35 The American Cancer
Society along with Massachusetts General Hospital pub-
lished a National Cancer Database report that focused on
the declining use of postoperative RT after radical pros-
tatectomy for prostate cancer with adverse features be-
tween 2005 and 2011.36 The adverse features were either
pathologic T3/4 or positive margins. Overall, the use of
postoperative radiation in this high-risk population
decreased by approximately 2% (9.1% to 7.3%) across the
United States. Geographically, the article showed that the
majority of patients received surgery alone versus the
addition of radiation with or without hormones in the
Midwest (89% vs 8.9%) and South (91% vs. 7.3%). These
regions encapsulate the Appalachian population. Also, the
odds ratio showed that patients in the South were less
likely to receive postoperative radiation compared with
those in the Northeast.
Although there is sparse data on the use of RT for
prostate cancer in the Appalachian region, we can use the
available literature to state that disparity in radiation
management is likely.
Head and neck cancer
Reports on the disparities of RT for head and neck
cancer (HNC) are sparse, and we were unable to find
reports targeting this specific subset. However, data are
available that tangentially reflect radiation delivery in this
population. A SEER analysis of patients with HNC who
were treated between 2007 and 2010 was reported in
2016.37 The retrospective analysis showed that Medicaid
patients were less likely to be treated with definitive ra-
diation and/or surgery. Also, patients with Medicare
coverage or no insurance were less likely to have
definitive treatment and present with metastatic disease.
Patients in disadvantaged areas such as the Appalachian
region are more likely to be uninsured or have
government-sponsored insurance as opposed to private
insurance. Thus, they may also have a higher risk of not
receiving definitive RT.
Harvard also conducted a SEER analysis on the use of
intensity modulated RT (IMRT) and conformal RT for
HNC.38 The authors showed that having a higher median
income predicted for a higher use of IMRT. The inter-
action seemed to have a linear relationship because the
second lowest income quartile had a higher use of IMRT
than the lowest income quartile. Because IMRT has been
shown to decrease morbidity,39 an increase in toxicity
from treatment may dissuade this patient population from
receiving or completing RT. Because patients in the Ap-
palachian region are usually low income, this study may
pertain to care in their community.
Although there is sparse data regarding use of RT in
this population, income and insurance seem to be asso-
ciated with receipt and type of care. This shows the need
for more reports targeting this patient population.
Esophageal cancer
Although the disparities in incidence rates for esoph-
ageal cancer, lymphoma/leukemia, and other miscella-
neous cancers are not as large, they still exist. For
esophageal cancer, the incidence in Appalachian men is
9.0 cases per 100,000 compared with 8.5 cases per
100,000 for non-Appalachian men (P < .05).14 When
specifically looking at adenocarcinomas of the esophagus,
this difference becomes much more pronounced. Ac-
cording to a study by Hebert et al. on esophageal cancer
disparities in South Carolina, a steady increase in the
incidence of esophageal adenocarcinomas was observed
since the late 1980s, with rates rising at approximately 3%
to 4% per year.40 Furthermore, this increase is predomi-
nantly seen in the European-American population.40
Another study, from 2005, estimated the increase in
incidence of esophageal adenocarcinoma to be in the
range of 300% to 500% over the last 40 years (contem-
porary to the time of the study) and again predominantly
in European-Americans.41 One hypothesis suggests that
the geographic pattern of incidence of esophageal
adenocarcinoma overlaps that of obesity fairly substan-
tially, which could in part explain the increased rates of
esophageal adenocarcinoma in these areas.41 Although
this disparity exists and some research has been done into
why it exists, there is very little research on the impact of
any disparities in the receipt of treatment on overall
survival.
Hematologic malignancies
Although RT has a more limited role in leukemia, there
are disparities with regard to leukemia incidence and
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survival between Appalachian and non-Appalachian pa-
tients that need to be addressed. Appalachian men have a
leukemia incidence of 16.9 cases per 100,000 compared
with 16.7 cases per 100,000 for non-Appalachian men.
Appalachian women have a leukemia incidence of 10.4
cases per 100,00 in comparison with 10.2 cases per
100,000 for non-Appalachian women.14
In a paper analyzing the geographical variation in
survival outcomes for adult patients with acute myeloid
leukemia within the state of North Carolina, Medicaid
patients had an increased likelihood of death when
compared with patients covered by private insurance
(hazard ratio, 1.36; confidence interval, 1.00-1.85; P <
.05).42 Also, as an independent association, patients who
did not undergo allogenic hematopoietic stem cell trans-
plantation (standard of care for definitive treatment)
within 1 year of diagnosis had a hazard ratio of 2.09
compared with those who were able to receive allogenic
hematopoietic stem cell transplantation (confidence in-
terval, 1.15-3.83; P < .05).42 Although these data are for
hematopoietic stem cell transplantation, access to RT may
have a role to play in this disparity because total body
irradiation is a prerequisite for stem cell transplantation.
Although data are sparse, there is some context for
increasing research of radiation-related cancer disparities
for esophageal cancer, lymphoma, leukemis, and other
miscellaneous cancers.
Breast cancer
Multiple studies have suggested that women in
Appalachia are at a higher risk for inadequate health
access and appropriate clinical screening for breast
cancer.43e48 Using central cancer registry data, Anderson
et al.44 showed that less-populated counties in 3
Appalachian states were statistically significantly
underscreened, especially for the early detection of locally
advanced breast cancer. Another study of 344 women in
North Carolina43 reported that up to one third of patients
did not receive RT after breast-conserving surgery (BCS),
and risk factors included living in less populated counties,
having BCS at smaller hospitals, and residing in counties
that were specialist scarce. Similar findings were reported
in South Carolina.49 Having on-site RT availability
increased breast-conserving therapy rates at a community
hospital.50 Surgeons were also less likely to refer patients
for adjuvant therapies if the patient had Medicaid
coverage or was not insured.45
Additionally, working women, especially those
receiving aggressive treatments, experienced significant
employment disruptions.51 Two studies using the Ken-
tucky Cancer Registry reported that postmastectomy47
and whole-breast52 RT were still vastly underused,
especially for older and poorer patients in rural regions.
Overall, only 66% of women received breast-conserving
therapy between 1998 and 2007.52 Older age, race, poor
socioeconomic status, and lack of access or further dis-
tance to a RT center were also noted as factors for more
women choosing mastectomy or forgoing RT altogether
after BCS in Appalachian states.48,53e56 In rural Virginia,
increased distance to an RT center was the only inde-
pendently predicted factor for increased mastectomy rates
in 20,094 patients.57 Similar findings were noted in North
Carolina58 and Kentucky59 (mountainous states).
There are multiple opportunities and needs for inter-
vention. A study that surveyed rural physicians in North
and South Carolina found that 55% failed to acknowledge
that adjuvant RT was required after lumpectomy for
breast cancer treatment.28 Another report also highlighted
the need for standardized pathologic information on sur-
gical specimen reports (eg, margin status, tumor size,
histologic grade, and angiolymphatic invasion) in both
urban and rural hospitals.60 In a large study of >4500
patients with breast cancer in Appalachian regions,61 the
authors pointed out that nonprofit hospitals in rural and
underserved areas may experience delays in diagnosing
new breast cancer cases. For many regions in Appalachia,
the main efforts remain reaching out to rural and very
rural populations and systemically improving the entire
care network at individual components (screening, diag-
nosis, surgery, and adjuvant therapies) with local health
care providers.62,63
Discussion
An unfortunate commonality of these disease sites in
Appalachian patients is the disparate access to optimal RT
as a result of a number of socioeconomic factors,
including but not limited to low income, lack of private
insurance, limited access to diagnostic and treatment
services (ie, colonoscopy for colorectal cancer screening),
paucities in both number and quality of radiation centers,
decreased access to up-to-date treatment recommenda-
tions, and the geographic region of the United States. In
fact, the median household income in Appalachia is 82%
of the U.S. median income, with only 19 Appalachian
counties having household incomes at or above the na-
tional mean.64
This patient population suffers from these socioeco-
nomic barriers and from the barrier of relative invisibility.
The disparities they face in receiving optimal care are not
as widely publicized as those of racial and ethnic mi-
norities, such as African Americans or Hispanic Ameri-
cans. Furthermore, an unfortunate reality is that many
people both within and outside the United States rely on
the flawed assumption that the overall wealth of the
United States is tangibly applicable to all of its citizens,
which may diminish their understanding of the great lack
of resources Appalachian patients with cancer face.
We hope that this manuscript will help to shed light on
the difficulties Appalachian patients with cancer face,
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with the goal of inspiring financial and policy-driven in-
terventions to tackle these difficulties, many of which may
be less formidable than they appear at first glance. Based
on the results elucidated in this manuscript for multiple
cancer sites, it may be wiser for the federal government to
increase aid to Appalachian patients with cancer rather
than (as the 2018 fiscal year budget proposed) completely
eliminating financial aid to this vulnerable
population.8e10
Furthermore, newer tools developed to identify pa-
tients at increased risk of toxicity after RT will need to be
governed with the priority of optimizing access to care
rather than optimizing profit.65,66 Otherwise, there is great
risk of exacerbating rather than alleviating the already
heavy burden facing Appalachian patients with cancer.
References
1. Delaney G, Jacob S, Featherstone C, Barton M. The role of radio-
therapy in cancer treatment: Estimating optimal utilization from a
review of evidence-based clinical guidelines. Cancer. 2005;104:
1129-1137.
2. McClelland S 3rd, Deville C, Thomas CR Jr, Jaboin JJ. An over-
view of disparities research in access to radiation oncology care. J
Radiat Oncol. 2016;5:437-444.
3. Miller RC, Goyal S, McClelland S 3rd, et al. ASTRO’s Advances in
Radiation Oncology e Success to date and future plans. Adv Radiat
Oncol. 2017;2:245-248.
4. McClelland S 3rd, Page BR, Jaboin JJ, Chapman CH, Deville C,
Thomas CR Jr. The pervasive crisis of diminishing radiation therapy
access for vulnerable populations in the United States e Part 1:
African-American patients. Adv Radiat Oncol. 2017;2:523-531.
5. McClelland S 3rd, Leberknight J, Guadagnolo BA, Coleman CN,
Petereit DG. The pervasive crisis of diminishing radiation therapy
access for vulnerable populations in the United States e Part 2:
American Indian patients. Adv Radiat Oncol. 2018;3:3-7.
6. McClelland S 3rd, Perez CA. The pervasive crisis of diminishing
radiation therapy access for vulnerable populations in the United
States e Part 3: Hispanic-American patients. Adv Radiat Oncol.
2018;3:93-99.
7. Friedell GH, Rubio A, Maretzki A, et al. Community cancer control
in a rural, underserved population: The Appalachian Leadership
Initiative on Cancer Project. J Health Care Poor Underserved.
2001;12:5-19.
8. Centers for Disease Control and Prevention. Cancer death rates–
Appalachia, 1994-1998. MMWR Morb Mortal Wkly Rep. 2002;51:
527-529.
9. Appalachian Regional Commission. Federal Co-Chair Earl F. Gohl.
Available at: https://www.arc.gov/about/FederalCoChair.asp.
Accessed May 18, 2017.
10. Executive Office of the President of the United States. America first:
A budget blueprint to make America great again. Major agency
budget highlights. Available at: https://www.govinfo.gov/content/
pkg/BUDGET-2018-BLUEPRINT/pdf/BUDGET-2018-BLUEPRINT.
pdf. Accessed May 18, 2017.
11. Friedell GH, Linville LH, Hullet S. Cancer control in rural Appa-
lachia. Cancer. 1998;83:1868-1871.
12. Portnoy B. Healthy people in rural America by the year 2000. In:
Couto RA, Simpson NK, Harris G, eds. Sowing Seeds in the
Mountains: Community-based Coalitions for Cancer Prevention
and Control. Bethesda, MD: Appalachia Leadership Initiative on
Cancer, National Cancer Institute; 1994:102-119.
13. Centers for Disease Control. Cancer prevention and control.
Available at: http://www.cdc.gov/cancer. Accessed May 18, 2017.
14. Wilson RJ, Ryerson AB, Singh SD, King JB. Cancer incidence in
Appalachia, 2004-2011. Cancer Epidemiol Biomarkers Prev. 2016;
25:250-258.
15. Centers for Disease Control. State-specific prevalence and trends in
adult cigarette smoking-United States, 1998-2007. MMWR Morb
Mortal Wkly Rep. 2009;58:221-226.
16. Van Ryn M, Burke J. The effect of patient race and socio-economic
status on physicians’ perceptions of patients. Soc Sci Med. 2000;50:
813-828.
17. Casey MM, Call KT, Klingner JM. Are rural residents less likely to
obtain recommended preventive healthcare services? Am J Prev
Med. 2001;21:182-188.
18. Henderson LM, Jones LM, Marsh MW, Benefield T, Rivera MP,
Molina PL. Lung cancer screening practices in North Carolina CT
facilities. J Am Coll Radiol. 2017;14:166-170.
19. Simmerman EL, Thomson NB 3rd, Dillard TA, et al. Free lung
cancer screening trends toward a twofold increase in lung cancer
prevalence in the underserved Southeastern United States. South
Med J. 2017;110:188-194.
20. Hua X, Ward KC, Gillespie TW, Lipscomb J, Goodman M. Non-
small cell lung cancer treatment receipt and survival among African-
Americans and whites in a rural area. J Community Health. 2014;39:
696-705.
21. Steele CB, Pisu M, Richardson LC. Urban/rural patterns in receipt
of treatment for non-small cell lung cancer among black and white
Medicare beneficiaries, 2000-2003. J Natl Med Assoc. 2011;103:
711-718.
22. Nadpara PA, Madhavan SS, Tworek C. Disparities in lung cancer
care and outcomes among elderly in a medically underserved state
population-A cancer registry-linked database study. Popul Health
Manag. 2016;19:109-119.
23. Singh R, Goebel M, Lynne J. Rural disparities in cancer care: A
review of its implications and possible interventions. W V Med J.
2016;112:76-82.
24. Lengerich EJ, Tucker TC, Powell RK, et al. Cancer incidence in
Kentucky, Pennsylvania, and West Virginia: disparities in Appa-
lachia. J Rural Health. 2005;21:39-47.
25. Fleming ST, Love MM, Bennett K. Diabetes and cancer screening
rates among Appalachian and non-Appalachian residents of Ken-
tucky. J Am Board Fam Med. 2011;24:682-692.
26. Hines RB, Markossian TW. Differences in late-stage diagnosis,
treatment, and colorectal cancer-related death between rural and
urban African Americans and whites in Georgia. J Rural Health.
2012;28:296-305.
27. Aneja S, Yu J. Radiation oncologist density and colorectal cancer
mortality. J Clin Oncol. 2011;29:605.
28. Hatzell TA, Ricketts TC, Tropman SE, Paskett ED, Cooper MR.
Rural physicians’ understanding of the state-of-the-art in breast,
colon and rectum cancer treatment. Cancer Causes Control. 1999;
10:261-267.
29. Brooks SE, Baquet CR, Gardner JF, Moses G, Ghosh A. Cervical
cancer–the impact of clinical presentation, health and race on sur-
vival. J Assoc Acad Minor Phys. 2000;11:55-59.
30. Brooks SE, Chen TT, Ghosh A, Mullins CD, Gardner JF,
Baquet CR. Cervical cancer outcomes analysis: Impact of age, race,
and comorbid illness on hospitalizations for invasive carcinoma of
the cervix. Gynecol Oncol. 2000;79:107-115.
31. Fleming S, Schluterman NH, Tracy JK, Temkin SM. Black and
white women in Maryland receive different treatment for cervical
cancer. PLoS One. 2014;9:e104344.
32. Seamon LG, Tarrant RL, Fleming ST, et al. Cervical cancer survival
for patients referred to a tertiary care center in Kentucky. Gynecol
Oncol. 2011;123:565-570.
33. Showalter TN, Camacho F, Cantrell LA, Anderson RT. De-
terminants of quality care and mortality for patients with locally
476 S. McClelland et al Advances in Radiation Oncology: OctobereDecember 2018
advanced cervical cancer in Virginia. Medicine (Baltimore). 2016;
95:e2913.
34. Prostate Cancer in Virginia. Virginia Cancer Registry (1970-1997).
2000.
35. American College of Surgeons. National cancer data base prostate
cancer statistics. Available at: http://www.facs.org:80/about_
college/acsdept/cancer_dept/programs/ncdb/whatsncdb.html. Accessed
October 30, 2017.
36. Sineshaw HM, Gray PJ, Efstathiou JA, Jemal A. Declining use of
radiotherapy for adverse features after radical prostatectomy: Results
from the national cancer data base. Eur Urol. 2015;68:768-774.
37. Inverso G, Mahal BA, Aizer AA, Donoff RB, Chuang SK. Health
insurance affects head and neck cancer treatment patterns and out-
comes. J Oral Maxillofac Surg. 2016;74:1241-1247.
38. Sher DJ, Neville BA, Chen AB, Schrag D. Predictors of IMRT and
conformal radiotherapy use in head and neck squamous cell carci-
noma: A SEER Medicare analysis. Int J Radiat Oncol Biol Phys.
2011;81:e197-e206.
39. Nutting CM, Morden JP, Harrington KJ, et al. Parotid-sparing in-
tensity modulated versus conventional radiotherapy in head and
neck cancer (PARSPORT): A phase 3 multicentre randomised
controlled trial. Lancet Oncol. 2011;12:127-136.
40. Hebert JR, Adams SA, Daguise VG, et al. Esophageal cancer dis-
parities in South Carolina: early detection, special programs, and
descriptive epidemiology. J S C Med Assoc. 2006;102:201-209.
41. Shaheen NJ. Advances in Barrett’s esophagus and esophageal
adenocarcinoma. Gastroenterology. 2006;128:1554-1566.
42. Freeman AT, Meyer A, Smitherman AB, et al. Statewide geographic
variation in outcomes for adults with acute myeloid leukemia in
North Carolina. Cancer. 2016;122:3041-3050.
43. Anderson RT, Kimmick GG, Camacho F, et al. Health system
correlates of receipt of radiation therapy after breast-conserving
surgery: A study of low-income Medicaid-enrolled women. Am J
Manag Care. 2008;14:644-652.
44. Anderson RT, Yang TC, Matthews SA, et al. Breast cancer
screening, area deprivation, and later-stage breast cancer in Appa-
lachia: Does geography matter? Health Serv Res. 2014;49:546-567.
45. Bickell NA, LePar F, Wang JJ, Leventhal H. Lost opportunities:
Physicians’ reasons and disparities in breast cancer treatment. J Clin
Oncol. 2007;25:2516-2521.
46. Christiansen N, Chen L, Gilmore J, Pechar D, Szabo S. Association
between African American race and outcomes in patients with
nonmetastatic triple-negative breast cancer: A retrospective analysis
by using results from the Georgia Cancer Specialist Database. Clin
Breast Cancer. 2012;12:270-275.
47. Dragun AE, Huang B, Gupta S, Crew JB, Tucker TC. One decade
later: Trends and disparities in the application of post-mastectomy
radiotherapy since the release of the American Society of Clinical
Oncology clinical practice guidelines. Int J Radiat Oncol Biol Phys.
2012;83:e591-e596.
48. Elward KS, Penberthy LT, Bear H, Swartz DM, Boudreau RM,
Cook SS. Variation in the use of breast-conserving therapy for
Medicare beneficiaries in Virginia: Clinical, geographic, and
hospital characteristics. Clin Perform Qual Health Care. 1998;6:
63-69.
49. Samson ME, Porter NG, Hurley DM, Adams Sa, Eberth JM. Dis-
parities in breast cancer incidence, mortality, and quality of care
among African American and European American women in South
Carolina. South Med J. 2016;109:24-30.
50. Hahn CA, Marks LB, Chen DY, Lind PA, Lind HM,
Prosnitz LR. Breast conservation rates-barriers between tertiary
care and community practice. Int J Radiat Oncol Biol Phys. 2003;
55:1196-1199.
51. Jagsi R, Abrahamse PH, Lee KL, et al. Treatment decisions and
employment of breast cancer patients: Results of a population-based
survey. Cancer. 2017;123:4791-4799.
52. Dragun AE, Huang B, Tucker TC, Spanos WJ. Disparities in the
application of adjuvant radiotherapy after breast-conserving surgery
for early stage breast cancer: Impact on overall survival. Cancer.
2011;117:2590-2598.
53. Guy GP Jr, Lipscomb J, Gillespie TW, Goodman M,
Richardson LC, Ward KC. Variations in guideline-concordant breast
cancer adjuvant therapy in rural Georgia. Health Serv Res. 2015;50:
1088-1108.
54. Sio TT, Chang K, Jayakrishnan R, et al. Patient age is related to
decision-making, treatment selection, and perceived quality of life in
breast cancer survivors. World J Surg Oncol. 2014;12:230.
55. Royak-Schaler R, Pelser C, Langenberg P, et al. Characteristics
associated with the initiation of radiation therapy after breast-
conserving surgery among African American and white women
diagnosed with early-stage breast cancer in Maryland, 2000-2006.
Ann Epidemiol. 2012;22:28-36.
56. White A, Richardson LC, Krontiras H, Pisu M. Socioeconomic
disparities in breast cancer treatment among older women. J
Womens Health (Larchmt). 2014;23:335-341.
57. Schroen AT, Brenin DR, Kelly MD, Knaus WA, Slingluff CL Jr.
Impact of patient distance to radiation therapy on mastectomy use in
early-stage breast cancer patients. J Clin Oncol. 2005;23:7074-7080.
58. Wheeler SB, Kuo TM, Durham D, Frizzelle B, Reeder-Hayes K,
Meyer AM. Effects of distance to care and rural or urban residence
on receipt of radiation therapy among North Carolina Medicare
enrollees with breast cancer. N C Med J. 2014;75:239-246.
59. Yao N, Matthews SA, Hillemeier MM, Anderson RT. Radiation
therapy resources and guideline-concordant radiotherapy for early-
stage breast cancer patients in an underserved region. Health Serv
Res. 2013;48:1433-1449.
60. Imperato PJ, Waisman J, Wallen MD, Llewellyn CC, Pryor V.
Improvements in breast cancer pathology practices among medicare
patients undergoing unilateral extended simple mastectomy. Am J
Med Qual. 2003;18:164-170.
61. Louis CJ, Clark JR, Hillemeier MM, Camacho F, Yao N,
Anderson RT. The effects of hospital characteristics on delays in
breast cancer diagnosis in Appalachian communities: A population-
based study. J Rural Health. 2018;34:S91-S103.
62. Markossian TW, Hines RB. Disparities in late stage diagnosis,
treatment, and breast cancer-related death by race, age, and rural
residence among women in Georgia. Women Health. 2012;52:317-
335.
63. Markossian TW, Hines RB, Bayakly R. Geographic and racial
disparities in breast cancer-related outcomes in Georgia. Health Serv
Res. 2014;49:481-501.
64. Pollard K, Jacobsen LA. The Appalachian Region: A data overview
from the 2006-2010 American community survey chartbook.
Available at: http://www.arc.gov/assets/research_reports/PRB-Data
Overview-2012.pdf. Accessed July 31, 2018.
65. Palmer JD, Patel TT, Eldredge-Hindy H, et al. Patients undergoing
radiation therapy are at risk of financial toxicity: a patient-based
prospective survey study. Int J Radiat Oncol Biol Phys. 2018;101:
299-305.
66. McClelland S 3rd, Jaboin JJ. Will financial toxicity screening help
or harm minority patient access to radiation therapy? Int J Radiat
Oncol Biol Phys. 2018;101:999-1000.
Advances in Radiation Oncology: OctobereDecember 2018 RT access disparities for Appalachian patients 477
